Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
Telix announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced in February 2021.1 The aim of this project was to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA2 and utilising the beta-emitting isotope rhenium-188 (188Re).
The outcomes from the research project – which included a pre-clinical and first-in-human evaluation – have been published in the latest issue of the Journal of Nuclear Medicine.
To read more please visit:
Source: Telix